Macro and Strategy Research - The report emphasizes the need for "high-quality" development, with a focus on technology and reform as the main themes for the upcoming five years [2][3] - The "15th Five-Year Plan" will specifically highlight "technological self-reliance" and "comprehensive deepening of reform," indicating a shift towards more concrete and detailed goals compared to the previous plan [2][3] - The modern industrial system will prioritize "intelligent, green, and integrated" development, with advanced manufacturing playing a crucial role [3] - The report stresses the importance of domestic circulation and consumer demand, aiming to enhance living standards and stimulate new consumption [4] - There is a strong emphasis on social welfare, including education and social security, to address the immediate concerns of the populace [5] - The report outlines a commitment to accelerate the green transition and build a new energy system, with specific targets for carbon neutrality and renewable energy [6] Fixed Income Research - The report notes a narrow fluctuation in interest rates, with the yield curve flattening, indicating a stable but cautious market environment [12][14] - Recent fiscal data shows an improvement in tax revenue due to inflation, while government spending is increasingly focused on technology and public welfare [12] - The issuance of local government bonds has been significant, with a total of 789.5 billion yuan issued, aimed at stabilizing economic operations in the fourth quarter [13] - The bond market is currently influenced by uncertainties in U.S.-China relations and expectations of monetary policy adjustments [14] Industry Research - The report highlights significant achievements by Chinese pharmaceutical companies at the ESMO conference, showcasing advancements in cancer treatment and innovative therapies [18][19] - A notable collaboration between Innovent Biologics and Takeda Pharmaceuticals has been established, with a potential total deal value of up to 11.4 billion USD, marking a significant milestone in the Chinese biopharmaceutical sector [19][20] - The report indicates a mixed performance in the pharmaceutical sector, with a slight decline in the industry index, but suggests that the outlook remains positive due to ongoing innovation and market opportunities [19][20]